Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
NCT ID: NCT01434524
Last Updated: 2011-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
56 participants
INTERVENTIONAL
2007-04-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life
NCT00945568
The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer
NCT02327819
Effect of Preoperative Supplementation in Insulin Resistance
NCT00657124
BCAA in Patients Undergoing Gastric Cancer Surgery
NCT06340399
Late Evening Supplementation With Branched Chain Amino Acids in Liver Transplantation
NCT02407769
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
normal dietary
No interventions assigned to this group
LIVACT
The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
LIVACT
LIVACT contains 13.0 g of free amino acids
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LIVACT
LIVACT contains 13.0 g of free amino acids
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* the presence of distant metastases, or
* serious impairment of organ function due to respiratory, renal, or heart disease.
16 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kochi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Takehiro Okabayashi
Kochi Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Takehiro Okabayashi, MD
Role: PRINCIPAL_INVESTIGATOR
Kochi Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kochi Medical School
Nankoku, Kochi, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIVACT 0801
Identifier Type: OTHER
Identifier Source: secondary_id
LIVACT 0801
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.